



ABIVAX to Present Phase IIa Clinical Data on ABX464 during NIH/NIAID-Sponsored Strategies for an HIV Cure Meeting 2016

November 16, 2016

Paris, November 16th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company is presenting clinical data on ABX464, ABIVAX's first-in-class drug candidate for the treatment of patients with HIV/AIDS, during this week's NIH / NIAID-sponsored Strategies for an HIV Cure Meeting 2016 in Bethesda, MD. ABIVAX's presentation is entitled, "Antiviral activity and safety of ABX464".